ArticleFrontiers in immunology2026
Case Report: Ultrasound features of pathological complete response in middle and low rectal cancer with high microsatellite instability after neoadjuvant immunotherapy: a case series.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate assessment of complete clinical response following neoadjuvant chemoradiotherapy remains challenging, and radiological evaluation criteria established for this treatment modality may not be applicable to neoadjuvant immunotherapy (NIT). Currently, there are no published studies describing the ultrasound features of pathological complete response (pCR) in patients with microsatellite instability-high (MSI-H) rectal cancer following NIT. In this case series, we comparatively analyzed multimodal transrectal ultrasound (TRUS) features before and after NIT in three patients with MSI-H mid- to low-rectal cancer. Despite imaging findings suggestive of residual lesions, two patients achieved pCR as confirmed by postoperative pathology, and one patient had no definite atypical components identified on ultrasound-guided biopsy. Our preliminary observations suggest that multimodal TRUS features, including reduced lesion size, diminished vascularity, heterogeneous hypoenhancement with non-enhancing areas on contrast-enhanced ultrasound, and reduced stiffness on shear wave elastography, may serve as potential imaging indicators of pCR in patients with MSI-H mid- to low-rectal cancer. Ultrasound-guided biopsy may provide complementary diagnostic information for confirming pCR in cases with persistent imaging abnormalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.